Press Releases

May 16, 2022
Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC)
BUFFALO, N.Y. , May 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a clinical trial collaboration
Printer Friendly Version 
May 10, 2022
Athenex Provides First Quarter 2022 Financial Results and Business Update
Reports 1Q product sales of $29.0M , up 42% year-over-year Encouraging interim update from ANCHOR study of KUR-502 presented at ASTCT with 60% overall response rate (ORR) and 6-month complete response (CR) rate of 29% in the NHL cohort Abstract for KUR-501 in GINAKIT2 study accepted at ASGCT; 25%
Printer Friendly Version 
May 02, 2022
Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma at the ASG
Data presented by investigators from the Texas Children’s Cancer Center’s Center for Advanced Innate Cell Therapy and Baylor College of Medicine   Data demonstrate expansion of CAR-NKT cells post-transfer in all patients, and objective responses in patients with relapsed/refractory neuroblastoma
Printer Friendly Version 
April 29, 2022
Athenex to Provide Corporate and Financial Update for the First Quarter 2022 on May 10, 2022
BUFFALO, N.Y. , April 29, 2022 (GLOBE NEWSWIRE) -- Athenex   (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a
Printer Friendly Version 
April 25, 2022
Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular (“Tandem”) Meetings of ASTCT and CIBMTR
Interim analysis provides response data from 7 evaluable patients including two additional patients, one with non-Hodgkin lymphoma (NHL) and one with acute lymphoblastic leukemia (ALL) Six-month CR rate of 29%, including 1 ongoing CR at 34 weeks in heavily pretreated patients Encouraging response
Printer Friendly Version 
March 16, 2022
Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Announces Strategic Pivot to Focus on Cell Therapy Programs Receives FDA Clearance for IND to Expand CD19 CAR-NKT ANCHOR to a Multi-center Study Implementing Significant Cost Reduction Plan Targeting >50% Reduction in Operating Expenses Plans to Extend Cash Runway in 2022 Through Monetization of
Printer Friendly Version 
March 14, 2022
CORRECTION: Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 16, 2022
BUFFALO, N.Y. , March 14, 2022 (GLOBE NEWSWIRE) -- Athenex   (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a
Printer Friendly Version 
March 07, 2022
Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 15, 2022
BUFFALO, N.Y. , March 07, 2022 (GLOBE NEWSWIRE) -- Athenex   (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a
Printer Friendly Version 
February 22, 2022
Athenex Announces Appointment of Chief Financial Officer
BUFFALO, N.Y. , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr.
Printer Friendly Version 
February 15, 2022
Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility
BUFFALO, N.Y. , Feb. 15, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the close of the sale of its
Printer Friendly Version 
February 09, 2022
Athenex to Present at the 11th Annual SVB Leerink Global Healthcare Conference
BUFFALO, N.Y. , Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau , CEO and Board
Printer Friendly Version 
January 12, 2022
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
BUFFALO, N.Y. , Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a
Printer Friendly Version